# A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

Source: https://onco.cc/trials/nct06632405/  
OnCo record `nct06632405` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab and nab-paclitaxel in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting.

## Summary

A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC is a phase 2, randomised interventional study registered as NCT06632405 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 60 participants, started 2025-04-01 and due to reach its primary completion in 2027-03-31. Interventions recorded: Camrelizumab; Nab paclitaxel; Levocetirizine Hydrochloride. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "Confirmed recurrent and metastatic triple negative breast cancer by imaging and pathology (ER negative (IHC ER positive percentage \< 1%), PR negative (IHC PR positive percentage \< 1%), HER2 negative (IHC -/+or IHC++but FISH/CISH -)), at least one measurable focus meeting the RECIST v1". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06632405
- Phase: 2
- Setting: Camrelizumab Plus Nab-paclitaxel and Anti-histamine Drug Levocetirizine in Metastatic or Recurrent Triple-negative Breast Cancer: a Randomized, Double-arm, Phase 2 Randomized Controlled Trial
- Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06632405: https://clinicaltrials.gov/study/NCT06632405

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06632405.json